The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis. Issue 10 (3rd October 2017)

• Record Type: Journal Article
• Authors: Wang, Li; Luo, Lan; Gao, Zhe; Liu, Shu-Feng; Liu, Cheng-Jun; Ma, De-Xun; Chen, Ji-Gang; Cao, Wu-Rui; Yin, Ai-Min; Xu, Jia-Wen; Wang, Song-Lei; Zhuo, Du-Jun; Geng, Bin; Zhao, Sha-Sha; Wang, Fei-Yan; Yang, Nan; Guan, Li-Xun; Gu, Zhen-Yang; Gao, Chun-Ji
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 10(2017)
• Page Start: 2452
• Page End: 2459
• Publication Date: 2017-10-03
• Subjects: Cerebrospinal fluid -- interleukin-10 -- central nervous system lymphoma -- meta-analysis -- diagnosis -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1289523
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Central nervous system lymphoma (CNSL) presents diagnostic and prognostic challenges. The aim of this meta-analysis was to evaluate the diagnostic and prognostic value of interleukin (IL)-10 in cerebrospinal fluid (CSF) for CNSL comprehensively. PubMed and Cochrane Library databases were searched through September 2016. Four studies with 212 CNSL patients and 262 control patients were included. The pooled sensitivity and specificity of CSF IL-10 for diagnosing CNSL were 81% (95% CI: 66–91%) and 97% (95% CI: 83–100%), respectively. The summary receiver operating characteristic (SROC) curve indicated that the area under the curve was 0.95 (0.93–0.97). The ROC curve based on extracted individual data showed that the optimal cutoff value was 6.88 pg/ml. Moreover, elevated CSF IL-10 was found to be associated with shorter progression-free survival (hazard ratio: 2.89, 95% CI: 1.13–7.41, p = .027). In conclusion, our meta-analysis showed that CSF IL-10 is an effective diagnostic and prognostic biomarker for CNSL.